OAK-PB — Brookfield Oaktree Holdings, LLC

NYSE · Financials · Capital Markets · CIK 1403528 ·
Last close
$20.90
Market Cap
52W High
$22.23
52W Low
$19.88
ADV30
14,173
Next earnings
Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment. It is also developing TVGN 920 which is in preclinical trial for treating cervical cancer; TVGN 960 which is in preclinical trial for treating oropharyngeal cancer; TVGN 601 which is in preclinical trial for treating multiple sclerosis; TVGN 930 which is in preclinical trial for treating Epstein-Barr virus associated lymphomas; and TVGN 116 a product candidate targeted at hepatitis B and is in preclinical trial. Tevogen Bio Holdings Inc. was formerly known as Tevogen Bio Inc. and changed its name to Tevogen Bio Holdings Inc. in February 2024. The company was founded in 2020 and is headquartered in Warren, New Jersey.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Dec 2024 140,320,000 140,320,000 182,256,000 43,591,000 7,073,432,000 1,602,984,000
Dec 2023 112,449,000 112,449,000 135,350,000 31,933,000 7,555,933,000 1,634,479,000
Dec 2022 59,827,000 59,827,000 245,617,000 25,542,000 5,654,889,000 1,565,837,000
Dec 2021 150,416,000 150,416,000 407,834,000 108,912,000 14,397,849,000 10,401,953,000

Annual Trend (SEC EDGAR, last 10y)

Revenues vs Net Income (last 10y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2024 688,790,000 951,454,000 221,177,000 7,073,432,000 1,602,984,000
Dec 2023 1,101,702,000 1,723,339,000 203,646,000 7,555,933,000 1,634,479,000
Dec 2022 1,454,410,000 3,277,748,000 631,660,000 5,654,889,000 1,565,837,000
Dec 2021 429,064,000 1,194,294,000 165,719,000 14,397,849,000 10,401,953,000
Dec 2020 928,987,000 2,853,426,000 154,839,000 10,394,115,000 7,798,780,000
Dec 2019 1,386,079,000 3,598,433,000 223,418,000 9,264,762,000 6,696,371,000
Dec 2018 52,732,000 10,432,178,000 6,982,839,000
Dec 2017 54,915,000 9,014,796,000 6,133,631,000
Dec 2016 254,490,000 439,674,000 28,078,000 7,649,110,000 5,419,892,000
Dec 2015 50,819,000 286,793,000 38,253,000 51,762,731,000 11,781,512,000

TTM Snapshot

Revenues TTM
$463,012,000
NetIncome TTM
$209,978,000
OpCashFlow TTM
$0
Assets (Latest)
$7,073,432,000
Forward EPS

Peers — same industry

TickerNameMarket CapLastDaily %
MS MORGAN STANLEY $330.78B $210.42
GS GOLDMAN SACHS GROUP INC $300.43B $1018.38
SCHW SCHWAB CHARLES CORP $183.03B $105.24
BLK BlackRock, Inc. $169.01B $1090.39
GLD SPDR GOLD TRUST $96.71B $371.54

News headlines (Yahoo Finance, 1h cache)

Hybrid/Evergreen Funds: Vinson & Elkins Partner Samuel Francis, Live at Nasdaq
2025-11-20 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.